|
Name: Sibutramine
Type: Appetite suppressant
AKA: Meridia
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
Sibutramine, an anti-obesity medication, was introduced in the 1990s. It was used to treat obesity by suppressing appetite. Its development marked an advance in weight management treatments, though its use has been limited by concerns over cardiovascular side effects.
|
|
V. Legal Information
Sibutramine, an appetite suppressant, was withdrawn from many markets due to safety concerns. It is classified as a controlled substance in the U.S. and other countries due to its potential for abuse and adverse effects. Historically, its legal status has shifted from approved use to restricted or banned status following safety reviews and regulatory actions. [Source: UNODC].
US Federal Schedule - IV
Schedule IV drugs, substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Sibutramine is a weight loss medication that acts as an upper, increasing metabolism and reducing appetite. Short-term use can aid in weight loss, but long-term use may lead to cardiovascular issues and dependency. Overdose risks include severe cardiovascular effects and potential death. Safe use requires careful dosing and medical supervision. Recent research focuses on its effectiveness and safety profile.  |
|
VII. Psychological Effects
Sibutramine, a weight loss drug, affects serotonin and norepinephrine systems, leading to appetite suppression and mood elevation. Immediate effects include reduced appetite and mood improvement, lasting several hours. Long-term use may result in mood disturbances, cognitive impairments, and cardiovascular issues. Research emphasizes its impact on neurotransmitter systems and associated risks of psychological effects and long-term health issues.
 |
|
VIII. Culture
Sibutramine, an appetite suppressant, has no historical or cultural lore but gained attention in the late 20th century for weight loss. It was widely prescribed for obesity but faced significant controversies due to its cardiovascular risks. Modern cultural discussions focus on its safety and the ethics of weight loss medications. Proponents initially included healthcare providers and patients seeking weight loss solutions, while opponents highlight the serious health risks leading to its withdrawal from the market. Its cultural impact reflects ongoing debates about diet pills, health, and regulatory standards.
 |